KPTI reports Q1 GAAP EPS of -$1.24 and revenue of $35.07M, exceeding analyst projections by $0.25 and $3.67M respectively.
Karyopharm Therapeutics reported a first-quarter GAAP loss per share of -$1.24, beating expectations by $0.25. Revenue reached $35.07 million, up 16.8% year-over-year and $3.67 million above estimates.
U.S. net product revenue totaled $29.2 million for the quarter ended March 31, 2026, compared to $21.1 million in the same period last year. The results reflect stronger-than-anticipated performance in both earnings and sales metrics.
The company did not disclose immediate market reactions in the release.